Cart
×
Dyne Therapeutics: The clinical impact of the FORCE™ platform
Duchenne muscular dystrophy (DMD) – An update on the DELIVER trial of DYNE-251 in males with DMD mutations amenable to exon 51 skipping. WATCH HERE
Dyne Therapeutics Announces New Clinical Data from ACHIEVE Trial of DYNE-101 in DM1 and DELIVER Trial of DYNE-251 in DMD Demonstrating Compelling Impact on Key Disease Biomarkers and Improvement in Multiple Functional Endpoints
As early investors in Dyne Therapeutics, we are pleased to share they reported positive updates in their next-generation exon skipping program for Duchenne amenable to skipping exon 51. In their […]
Fireside Chat with Dyne Therapeutics on DYNE-251
Moving from Bench to Clinic to Deliver a Potentially Transformative Therapy for Duchenne Muscular Dystrophy Join us for a Fireside Chat discussing Dyne’s Phase 1/2 clinical trial, DELIVER, evaluating DYNE-251 […]
Clinical Hold of DYNE-251
On January 14th 2022, the U.S. FDA placed a clinical hold on Dyne’s Investigational New Drug (IND) submission for the launch of their clinical trial of DYNE-251, which targets Duchenne […]
Dyne Therapeutics Series B financing
CureDuchenne congratulates the incredible Dyne Therapeutics team, who recently announced closing $115M in equity financing to develop transformational therapies for patients with serious muscle diseases. We share this news in […]